ArticleFrontiers in public health2022
Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review.International journal for equity in health · 2025Pooled it
- Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016-2024.BMJ open · 2024Pooled it
- Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.Scientific reports · 2026Article
- Impact of China's National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia.Health data science · 2026Article
- Impact of six rounds of national drug price negotiation on availability, cost, use, and prices of targeted drugs in China.BMC health services research · 2025Article
- Programmes for pathology: improving health outcomes for low- and middle-income countries in the artificial intelligence paradigm.International health · 2025Article
- A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025Article
- Analysis of nationwide availability of negotiated drugs in China's National Reimbursement Drug List.Frontiers in public health · 2025Article
- Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China.BMC health services research · 2024Article
- The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.BMC public health · 2024Article
- The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.Frontiers in public health · 2024Article
- How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data.International journal for equity in health · 2023Article
- The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.Journal of global health · 2023Article
- Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.Frontiers in public health · 2023Article
- Access to anticancer medicines in public hospitals of Northwestern China.Frontiers in public health · 2023Article
- Trends and prescribing patterns of oral anti-neoplastic drugs: a retrospective longitudinal study.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In order to establish a long-term strategy for bearing the costs of anti-cancer drugs, the state had organized five rounds of national-level pricing negotiations and introduced the National Health Insurance Coverage (NHIC) policy since 2016. In addition, the National Healthcare Security Administration (NHSA) introduced the volume-based purchasing (VBP) pilot program to Nanjing in September 2019. Taking non-small cell lung cancer as an example, the aim of the study was to verify whether national pricing negotiations, the NHIC policy and the VBP pilot program had a positive impact on the accessibility of three targeted anti-cancer drugs. Methods: Based on the hospital procurement data, interrupted time series (ITS) design was used to analyze the effect of the health policy on the accessibility and affordability of gefitinib, bevacizumab and recombinant human endostatin from January 2013 to December 2020 in Nanjing, China. Results: The DDDs of the three drugs increased significantly after the policy implementation ( Conclusion: The accessibility of targeted anti-cancer drugs has increased significantly after the implementation of centralized prices, the NHIC policy and the VBP pilot program, and has shown sustained long-term growth. Multi-pronged supplementary measures and policy approaches by multiple stakeholders will facilitate equitable access to effective and affordable anti-cancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.